ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Non-Cash Investing and Financing Transactions (Details Textual) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2014
Deferred Finance Costs, Net		$ 30,210us-gaap_DeferredFinanceCostsNet	$ 30,210us-gaap_DeferredFinanceCostsNet
Clear Point Reusable Components [Member]
Transfer from Inventory to Property and Equipment	8,006	47,329
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	3,640	18,780	18,780
Boston Scientific Notes [Member]
Notes Payable Cancelled, Principal Amount			4,338,601
Warrant [Member]
Derivative, Fair Value, Net		$ 413,057	$ 413,057